Search

Your search keyword '"Arnott, Clare"' showing total 493 results

Search Constraints

Start Over You searched for: Author "Arnott, Clare" Remove constraint Author: "Arnott, Clare"
493 results on '"Arnott, Clare"'

Search Results

6. Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria

8. Effect of SGLT2 Inhibitors on Discontinuation of Renin–angiotensin System Blockade: A Joint Analysis of the CREDENCE and DAPA-CKD Trials

9. Protocol for a randomized controlled trial of medically tailored meals compared to usual care among individuals with type 2 diabetes in Australia

10. Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial

12. Protocol for a novel sodium and blood pressure reduction intervention targeting online grocery shoppers with hypertension – the SaltSwitch Online Grocery Shopping randomized trial

13. The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trial

14. Acceptability and feasibility of a chronic breathlessness diagnostic clinical algorithm in Australian primary care.

15. An overview of the CANVAS Program and CREDENCE trial: The primary outcomes and key clinical implications for those managing patients with type 2 diabetes.

18. Machine learning for prediction of chronic kidney disease progression: Validation of the Klinrisk model in the CANVAS Program and CREDENCE trial

19. Effects of SGLT2 inhibitors on cause-specific cardiovascular death in patients with chronic kidney disease: a meta-analysis of CKD progression trials

23. Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA1c, disease duration and treatment intensity: results from the CANVAS Program

27. The potential for reducing greenhouse gas emissions through disease prevention: a secondary analysis of data from the CREDENCE trial

31. Geographic and racial variability in kidney, cardiovascular and safety outcomes with canagliflozin: A secondary analysis of the CREDENCE randomized trial.

32. Effects of canagliflozin on total heart failure events across the kidney function spectrum: Participant‐level pooled analysis from the CANVAS Program and CREDENCE trial.

33. Prediction of new‐onset heart failure in patients with type 2 diabetes derived from ALTITUDE and CANVAS.

34. Blood pressure postpartum (BP2) RCT protocol: Follow-up and lifestyle behaviour change strategies in the first 12 months after hypertensive pregnancy

37. Effects of iron on cardiovascular, kidney and safety outcomes in patients with chronic kidney disease: a systematic review and meta-analysis

38. Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE Trial

41. Colchicine in Cardiovascular Disease: In-Depth Review

42. Secondary Analysis of the Salt Substitute and Stroke Study (SSaSS): Effects of Potassium-Enriched Salt on Cardiac Outcomes.

43. Estimated Lifetime Cardiovascular, Kidney and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Non-steroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria

49. The effects of canagliflozin in type 2 diabetes in subgroups defined by population‐specific body mass index: Insights from the CANVAS Program and CREDENCE trial

50. Clinical Pathway for Coronary Atherosclerosis in Patients Without Conventional Modifiable Risk Factors

Catalog

Books, media, physical & digital resources